Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIEGE: scheduling nab-paclitaxel with gemcitabine
ISRCTN71070888Phase 2Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Jan 2014
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
Phase 2, randomised, open-label trial of nab-paclitaxel and gemcitabine in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Progression-free survival. Started Jan 2014; status: completed.
02
Drugs
nab-paclitaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ISRCTN71070888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN71070888.